Many hepatitis C patients with cirrhosis or advanced fibrosis face liver failure and liver cancer
Sofosbuvir/ledipasvir cures most previously treated hepatitis C patients with cirrhosis
Sofosbuvir/ledipasvir with ribavirin cures most people with hepatitis C recurrence after liver transplantation
AbbVie 3D regimen cures recurrent HCV in most liver transplant recipients without cirrhosis
Merck's grazoprevir/elbasvir combo shows high cure rates, including for people with cirrhosis and HIV/HCV co-infection
Sofosbuvir/ledipasvir with ribavirin is highly effective for people with decompensated cirrhosis
People living with HIV have high survival rates after liver transplants due to HCC
Daclatasvir TRIO regimen has good cure rates for hepatitis C patients with or without cirrhosis
Sustained virological response to hepatitis C treatment reduces mortality, liver cancer and liver transplants
